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Abstract
Neurexins are a large family of neuronal plasma membrane proteins, which function as trans-synaptic receptors during
synaptic differentiation. The binding of presynaptic neurexins to postsynaptic partners, such as neuroligins, has been
proposed to participate in a signaling pathway that regulates synapse formation/stabilization. The identification of
mutations in neurexin genes associated with autism and mental retardation suggests that dysfunction of neurexins may
underlie synaptic defects associated with brain disorders. However, the mechanisms that regulate neurexin function at
synapses are still unclear. Here, we show that neurexins are proteolytically processed by presenilins (PS), the catalytic
components of the c-secretase complex that mediates the intramembraneous cleavage of several type I membrane
proteins. Inhibition of PS/c-secretase by using pharmacological and genetic approaches induces a drastic accumulation of
neurexin C-terminal fragments (CTFs) in cultured rat hippocampal neurons and mouse brain. Neurexin-CTFs accumulate
mainly at the presynaptic terminals of PS conditional double knockout (PS cDKO) mice lacking both PS genes in
glutamatergic neurons of the forebrain. The fact that loss of PS function enhances neurexin accumulation at glutamatergic
terminals mediated by neuroligin-1 suggests that PS regulate the processing of neurexins at glutamatergic synapses.
Interestingly, presenilin 1 (PS1) is recruited to glutamatergic terminals mediated by neuroligin-1, thus concentrating PS1 at
terminals containing b-neurexins. Furthermore, familial Alzheimer’s disease (FAD)-linked PS1 mutations differentially affect
b-neurexin-1 processing. Expression of PS1 M146L and PS1 H163R mutants in PS2/2 cells rescues the processing of b-
neurexin-1, whereas PS1 C410Y and PS1 DE9 fail to rescue the processing defect. These results suggest that PS regulate the
synaptic function and processing of neurexins at glutamatergic synapses, and that impaired neurexin processing by PS may
play a role in FAD.
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Introduction
Alzheimer’s disease (AD) is an age-related neurological disorder
characterized by progressive memory impairment and neurode-
generation. The majority of familial AD (FAD) cases are caused by
autosomal dominant mutations in the presenilin genes. Presenilins
(PS) are the catalytic components of c-secretase, an aspartyl
protease that cleaves a number of type I membrane proteins
involved in essential cell functions [1,2]. Cleavage of the b-amyloid
precursor protein (APP) by PS/c-secretase generates the b-
amyloid (Ab) peptides, the principal component of cerebral
plaques that accumulate in AD brains [3]. FAD-linked PS
mutations affect differentially the c-secretase-mediated cleavages
of APP or other substrates, altering the c-cleavage that generates
Ab peptides of different lengths and reducing the e-cleavage that
generates the soluble C-terminal intracellular domains [4]. PS
inactivation in glutamatergic neurons in PS1/PS2 conditional
double knockout (PS cDKO) mice results in synaptic plasticity and
memory impairment [5], which indicates that PS are essential for
neuronal function. The synaptic and memory deficits caused by
loss of PS function are independent of Ab accumulation and occur
through a largely uncharacterized synaptic mechanism. It has
been recently reported that PS regulate neurotransmitter release
during synaptic transmission [6]. These observations have led to
the hypothesis that loss of PS function may be a key process in the
physiopathology of FAD [7].
Neurexins are type I neuronal proteins that regulate synapse
assembly and maturation. Neurexins are encoded by three genes
each giving rise to longer a-neurexins and shorter b-neurexins in
hundreds of alternatively spliced isoforms at the extracellular
domains [8]. Neurexins mediate synapse formation by trans-
synaptic binding to several postsynaptic partners including
neuroligins, LRRTMs and GluRd2 [9–15]. In the neurexin-
neuroligin complex, the binding of b-neurexins with neuroligin-1
(+B) isoforms mediates glutamatergic differentiation, whereas
neuroligin-2 interacts with a- and b-neurexins and concentrates
at GABAergic synapses [12,16–19]. Despite the identification of a
number of neurexin partners, the mechanisms by which neurexin
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completely known. Interestingly, mutations in the NRXN1 gene
have been associated with autism and other brain disorders [20–
22], which indicates that neurexin dysfunction could underlie the
molecular basis of some mental diseases [23].
We explored the possibility that neurexins could be a substrate
for PS/c-secretase. Here we describe that neurexins are
sequentially processed by metalloprotease and PS/c-secretase
activities. Genetic inactivation of PS/c-secretase leads to accumu-
lation of neurexin C-terminal fragments (CTFs), the substrate of c-
secretase, mainly at presynaptic compartments and enhances
neurexin accumulation at glutamatergic synapses mediated by
neuroligin-1 (+B). Moreover, FAD-linked PS1 mutants differen-
tially affect the processing of b-neurexin-1. These results indicate
an important role for PS in regulating the synaptic function of
neurexins, and suggest that defects in neurexin signaling may be
involved in synaptic deficits associated with loss of PS function.
Materials and Methods
Ethics Statement
Animal procedures were performed in accordance with
institutional andnational guidelines following approval by the
Animal Care and Ethical Committee of the Universitat Auto `noma
de Barcelona (protocol # CEEA601) and the Ethics Committee of
the University of Seville (protocol #113).
Antibodies and reagents
The following commercially available primary antibodies were
used in this study: rat anti-HA (Roche); mouse anti-synaptobre-
vin2/VAMP2 (Synaptic Systems); rabbit anti-Presenilin 1 N-
terminal (1–65), rabbit anti-mouse/rat Presenilin 1 (Ab-2; 303–
316) and rabbit anti PS1 loop (263–407) (Merck) [24]; mouse anti-
CASK, mouse anti-N-Cadherin (clone 32), mouse anti-Nicastrin
(clone 35) and mouse anti-PSD95 (BD Biosciences); rabbit anti-a-
actin and mouse anti-b-actin (AC-15) (Sigma-Aldrich) and mouse
anti-synaptophysin (SVP-38; Sigma-Aldrich). Chicken anti-cyto-
neurexin antibodies have been previously described [11]. Cross-
absorbed secondary antibodies conjugated with Cy2, Cy3 and Cy5
were used in immunofluorescence experiments (Jackson Immu-
noResearch). In experiments with chemical inhibitors cells were
treated with 2.5 mM GM6001, 20 mM TAPI-1 and 5 mM GL189
(Calbiochem) and 1 mM N-[N-(3,5-difluorophenacetyl-L-alanyl]-
S-phenylglycine t-butyl ester (DAPT; Sigma-Aldrich) for 14 hours.
DNA and lentiviral constructs
For expression experiments in HEK293 cells, cDNAs were
cloned in a pCAGGS vector under control of the chicken b-actin
promoter. Transfected rat a- and b-neurexin isoforms contained a
HA-tag after the signal sequence. The neuroligin-1 splice isoform
used in this study contained A and B insertions and a HA-tag after
the signal sequence (named in the text as to HA-Nlg1), as
previously described [25]. In b-neurexin-1 DC mutant, amino
acids 413–468 corresponding to the cytoplasmic tail were deleted.
Expression plasmids encoding human PS1 and FAD-linked
variants PS1 M146L, PS1 H163R, PS1 C410Y and PS1 DE9
were subcloned in KpnI/BamHI sites of the pAG3Zeo vector under
the control of the b-actin promoter [26]. PS1 D385A subcloned in
EcoRI sites in pCDNA3.1 was kindly provided by Dr. P. Fraering
(E ´cole Polytechnique Fe ´de ´rale de Lausanne, Switzerland) [27]. For
infection of cultured hippocampal neurons, cDNAs were inserted
in a previously described lentiviral vector under the control of the
synapsin promoter (Syn) and upstream of a WPRE element [28].
Lentiviral vectors used in this study were: Syn-GFP-WPRE; Syn-
HA-bNrx1-WPRE; Syn-HA-bNrx1 DC-WPRE; Syn-PS1-WPRE
and Syn-PS1 D385A-WPRE.
Lentiviral particles were generated as previously described [29].
Briefly, HEK293T cells were transfected using the calcium
phosphate method with the lentiviral expression vector and two
packaging vectors: pCAG-VSVg, a plasmid expressing the VSV-G
envelope gene, and pCMVDR8.91, a plasmid expressing the gag/
pol genes. The supernatants containing the viral particles were
collected 48–60 hours after transfection and concentrated by
ultracentrifugation. For infection of hippocampal neurons, cultures
were transduced at the indicated day in vitro (DIV) by adding
concentrated lentivirus into the growing media.
Cell culture and transfection
Hippocampal tissues dissected from embryonic day 18–19 rat
brains were incubated with trypsin (Gibco) in Dulbecco’s modified
Eagle’s medium with high glucose (DMEM; Invitrogen) for 15
minutes at 37uC and mechanically dissociated with a Pasteur
pipette in DMEM medium supplemented with 10% fetal bovine
serum (HyClone), 44.4 mM D2(+)2glucose (Sigma), 2 mM
Glutamax (Gibco), and Penicillin/Streptomycin (100 units/ml
and 100 mg/ml, respectively; Gibco). Dissociated cells were plated
at a density of 32,000 cells/cm
2 in 24-well plate. The medium was
replaced 2 hours after plating with neurobasal medium (Gibco)
supplemented with B27 (Invitrogen), 2 mM Glutamax and
Penicillin/Streptomycin. Hippocampal neurons were transfected
using Lipofectamine 2000 (Invitrogen) at 10–14 DIV and fixed 2
days after transfection.
HEK293 cells were obtained from the American Type Culture
Collection and grown in DMEM supplemented with 10% fetal
bovine serum, 2 mM Glutamax and Penicillin/Streptomycin.
HEK293 cells were transfected using Lipofectamine (Invitrogen).
The mixed culture assays were performed essentially as described
previously [13]. Briefly, HEK293 cells were transfected with HA-
Nlg1 or GFP. Twenty-four hours after transfection, the cells were
trypsinized and resuspended in neurobasal medium supplemented
with 2 mM Glutamax, and cells were added into 14 DIV
hippocampal cultures at a density of 25,000 cells/cm
2 and
maintained in culture for 24 hours. Mouse embryonic fibroblasts
(MEF) derived from PS1/PS2 (+/+; control) or PS2/2 embryos
have been previously described [30]. Cells were transiently
transfected for 24–48 h with empty vector or pCAGGS-HA-
bNrx1 and pAG3Zeo-PS1 variants (PS1, PS1 M146L, PS1
H163R, PS1 C410Y and PS1 DE9) by using Lipofectamine 2000.
Mice and brain fractionation
Generation and characterization of PS12/2 and PS cDKO mice
have been previously described [5,31]. Control (fPS1/fPS1; PS2+/+)
and PS cDKO (fPS1/fPS1; PS22/2; a-CaMKII-Cre) mice were
generated by crossing PS1 cKO; PS2+/2 (fPS1/fPS1; PS2+/2;
a-CaMKII-Cre)w i t hf l o x e dPS1;P S 2 +/2 (fPS1/fPS1; PS2+/2)m i c e .
Age-matched littermate mice in a C57BL6/129 hybrid background
were used for this study.
Synaptic fractionations from mouse forebrains were prepared at
4uC essentially as described [32,33]. Adult mice (three individuals
per group) were rapidly decapitated, and cortices were dissected
and homogenized in ice-cold Buffer A (5 mM HEPES, pH 7.4,
0.32 M sucrose, 1 mM NaHCO3, 1 mM MgCl2, 0.5 mM CaCl2,
1 mM NaF and phosphatase and protease inhibitors (Roche) by
using a Teflon-glass homogenizer (12 strokes). The homogenate
corresponding to the total lysate was centrifuged (1,400 x g for
10 min) and the pellet (P1) was re-extracted with Buffer A,
homogenized (three strokes) and centrifuged (710 x g for 10 min).
The supernatants (S1 + S19) were combined and centrifuged
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resuspended in 3 ml ice-cold Buffer B (6 mM Tris, pH 8.0,
0.32 M sucrose, 1 mM NaHCO3, 1 mM NaF and phosphatase
and protease inhibitors) with a Teflon homogenizer (six strokes)
and loaded onto the top of a discontinuous sucrose gradient
(0.85 M, 1 M and 1.2 M sucrose solution) and centrifuged at
82,500 x g for 2 h. The synaptosome fraction was collected from
the interface of the 1 M–1.2 M sucrose layers, diluted in equal
volume of Buffer C (12 mM Tris HCl, pH 8.0, 1% Triton X-100)
and incubated on ice for 15 min. The suspension was spin at
32,800 x g for 1 h to obtain the supernatant (presynaptic fraction).
The pellet containing the postsynaptic fraction was resuspended in
cold-ice Buffer D (40 mM Tris, pH 8.0, 1% NP40). The protein
concentration was determined with the BCA protein assay kit
(Pierce).
Biochemical analysis
HEK293 cells and hippocampal neurons growing on 24-well
plates were lysed in lysis buffer (50 mM Tris HCl, pH 7.4, 1%
Triton X-100, 100 mM NaCl, 5 mM MgCl2, 0.1% SDS)
containing protease inhibitor mixture (Roche). Embryonic brain
(E17.5) or cortices from 2 month-old mice were homogenized in
RIPA-DOC buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl,
2.5 mM EDTA, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS, 1 mM, Na3VO4, 50 mM NaF, 1 mM phenylmethylsulfonyl
fluoride) supplemented with protease and phosphatase inhibitors.
When indicated, cell culture media were used as starting material
in immunoprecipitation experiments performed with the HA
antibody. The immune complexes were precipitated with the
Protein G Sepharose (GE Healthcare) and washed with pre-cooled
lysis buffer. Equivalent amounts of protein lysates were resolved on
8–14% SDS-PAGE gels and transferred to PDVF membranes
(Millipore). Immunoblotting was performed with the following
antibody concentrations: HA (1:1,000), Presenilin 1 N-terminal
(1:5,000), Presenilin 1 Ab-2 (1:500), CASK (1:200), N-Cadherin
(1:1,000), PS1 loop (1:5,000), Nicastrin (1:1,000), synaptophysin
(1:120,000), PSD-95 (1:2,000), cyto-neurexin (1:250–1:1,200), b-
actin (1:60,000) and a-actin (1:2,000). Immunoreactivity was
detected with secondary antibodies conjugated to horseradish
peroxidase (1:5,000; Jackson ImmunoResearch) and developed
with ECL Plus (GE Healthcare) or ECL kit (Perkin Elmer) using a
ChemiDoc XRS System (Bio-Rad). Protein images were captured
and quantified with the ImageJ software within a linear range of
detection for the ECL reagent.
Immunofluorescence and image analysis
Cell cultures were fixed with a 4% paraformaldehyde in
phosphate buffer containing 4% sucrose for 20 min. After fixation,
the cultures were permeabilized and blocked with 5% fetal bovine
serum in PBS containing 0.05% TritonX-100. Cells were
incubated with primary and secondary antibodies for 1–2 hours
in the same blocking solution. The following antibody concentra-
tions were used: HA (1:1,000), VAMP2 (1:3,000), Presenilin 1 N-
Terminal (1:500), Presenilin 1 Ab-2 (1:25) and Cyto-neurexin
(1:250). Cells were mounted using Fluoromount-G (SouthernBio-
tech).
The images were acquired on an Olympus Fluoview FV1000
confocal laser scanning microscope (objective: PLAPON 60X;
numerical aperture 1,42) using the same settings for photomulti-
plier voltage, gain and offset of all images. Maximal projections of
Z-stacked images were obtained and analyzed with ImageJ
software. The recruitment of neurexins and PS1 was quantified
as the relative number of pixels per cell area above a threshold
value. Thresholds were set such that most of the specific signal was
selected. Thresholding was applied to create a binary image
containing the positive pixels per each marker. The GFP or HA-
Nlg1 channels were used to create a mask covering the cell area by
drawing an outline around the transfected cells. The number of
positive pixels were normalized to the cell area and averaged in
each experimental condition. Data were plotted as mean 6 SEM.
Statistical significance was determined by ANOVA with depen-
dent post hoc Fisher’s multiple comparison test.
Results
Shedding of neurexins by metalloprotease- and c-
secretase-dependent cleavages
The proteolytic processing of neurexin proteins was investigated
in HEK293 cells, a mammalian cell line that expresses a functional
active c-secretase complex [34]. We transfected HEK293 cells
with a b-neurexin-1 isoform containing a HA-tag at the N-
terminal domain (HA-bNrx1). The expression of HA-bNrx1 was
studied by Western blotting in cell lysates using two different
antibodies: a HA antibody that recognizes the extracellular
domain, and a cyto-neurexin antibody raised against the common
cytoplasmic tail of neurexins [11]. The cyto-neurexin antibody
detected two bands of ,80 kDa and ,50 kDa, corresponding to
the glycosylated full-length b-neurexin-1 (bNrx-FL) and the
unglycosylated core protein, respectively (Fig. 1A). Interestingly,
the cyto-neurexin antibody detected two additional faint bands of
,12–15 kDa in the same cell lysates, which were not observed
with the HA antibody (Fig. 1A and data not shown). We
speculated that the lower molecular weight bands could represent
cleaved C-terminal fragments (neurexin-CTFs) generated by
proteolytic shedding of the extracellular domain of HA-bNrx1.
If so, such an activity might release the N-terminal extracellular
domain (bNrx-NTF) to the media. Accordingly, immunoprecip-
itation experiments followed by Western blotting with the anti-HA
antibody revealed the presence of bNrx-NTF in the media of
HEK293 cells transfected with HA-bNrx1 (Fig. 1A). Interestingly,
the apparent molecular weight of bNrx-NTF was ,15 kDa lower
than the bNrx-FL found in cell lysates (Fig. 1A), consistent with the
generation of neurexin-CTFs by a proteolytic shedding of the
mature protein.
Metalloproteases can proteolize the extracellular domain of a
number of transmembrane proteins resulting in shedding of the
soluble extracellular domain and the generation of membrane-
bound CTF, which subsequently becomes a substrate for the PS/
c-secretase complex [35]. To analyze whether the processing of
HA-bNrx1 required the activity of metalloproteases and PS/c-
secretase, we performed biochemical analysis in transfected
cultures treated with GM6001, a broad metalloprotease inhibitor,
or DAPT, a specific c-secretase inhibitor. We found that
GM6001 reduced both the levels of bNrx-NTF released to the
media and neurexin-CTF found in cell lysates (Fig. 1A).
Moreover, incubation with the PS/c-secretase inhibitor DAPT
increased basal accumulation of neurexin-CTFs in cell lysates,
whereas it did not affect the generation of bNrx-NTF (Fig. 1A).
To analyze whether other neurexin isoforms are processed by
PS/c-secretase, we transfected HEK293 cells with HA-aNrx1 or
HA-bNrx2 and their processing was analyzed by Western
blotting with the cyto-neurexin antibody. Similar to HA-bNrx1,
expression of HA-aNrx1 or HA-bNrx2 induced the basal
accumulation of neurexin-CTFs, which was further increased in
cultures incubated with DAPT (Fig. 1B). Recently, it has been
shown that the shedding of b-neurexin-3 ectodomain was
inhibited by the TACE/ADAM17 inhibitor TAPI-1 [36]. We
similarly found that TAPI-1, but not the BACE inhibitor GL189,
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HA-bNrx1- or HA-bNrx2-transfected cells (Fig. 1C). Together,
these results suggest a sequential shedding of neurexin isoforms
by metalloprotease- and c-secretase-dependent activities and that
inhibition of the PS/c-secretase results in the accumulation of
neurexin-CTFs.
Accumulation of neurexin-CTFs in presenilin-deficient
primary neurons
PS are the catalytic components of the c-secretase, an enzymatic
complex that cleaves the intramembrane domain of a number of
signaling proteins [4]. The proteolytic activity of c-secretase
depends on two aspartate residues in PS1, D257 and D385, which
Figure 1. Processing of neurexins by metalloprotease- and c-secretase-dependent cleavages. A) HEK293 cells were transfected with
vector or HA-bNrx1 and treated with DMSO (control), GM6001 or DAPT, as indicated. Left panels: Western blot experiments of cell lysates analyzed
with the cyto-neurexin antibody. Right panel: Western blot with an anti-HA antibody of HA-immunoprecipitates of conditioned media of transfected
cells. A cell lysate of HEK293 cells transfected with HA-bNrx1 was included in the same blot to show bNrx-FL. Arrow points at IgG heavy chains in
immunoprecipitates. B) HEK293 cells transfected with vector, HA-bNrx1, HA-bNrx2 or HA-aNrx1 were incubated with vehicle or DAPT, as indicated.
The presence of neurexin-CTFs was analyzed by Western blotting with the cyto-neurexin antibody. C) COS cells transfected with HA-bNrx1 (upper
panels) or HA-bNrx2 (lower panels) were incubated with DMSO (control) or with DAPT alone or in combination with TAPI-1, GL189, TAPI-1 and GL189,
or GM6001 inhibitors, as indicated. Neurexin-CTFs levels were studied by Western blotting with the cyto-neurexin antibody. a-Actin levels were used
as loading control.
doi:10.1371/journal.pone.0019430.g001
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residues result in the accumulation of c-secretase substrates in
neurons [27,37,38]. In order to study whether endogenous
neurexins are processed by a PS/c-secretase-dependent activity,
we first analyzed the processing of neurexins in cultured
hippocampal neurons treated with vehicle or DAPT. Biochemical
analysis of hippocampal neurons with the cyto-neurexin antibody
revealed a weak double band corresponding to endogenous
neurexin-CTFs that were robustly increased by treatment with
DAPT (Fig. 2A). Glycosylated full-length a- and b-neurexins were
detected as bands of ,150 and ,100 kDa, respectively (Fig. 2A).
As previously reported [39], N-cadherin-CTF was increased in
DAPT-treated hippocampal neurons (Fig. 2A).
We next generated lentiviral vectors (LV) expressing human
PS1 or PS1 D385A and performed a dominant-negative
approach to block PS1 activity in hippocampal neurons. These
lentiviral vectors contain the neuronal synapsin promoter, which
directs the expression of the exogenous proteins to .90% of
cultured neurons [28]. Infection of cultured hippocampal neurons
with LV-PS1 D385A robustly and similarly increased the levels of
neurexin-CTFs to the levels of control cultures treated with
DAPT (Fig. 2A). In contrast, expression of LV-PS1 did not result
in an increase of neurexin-CTFs. The expression of the
exogenous PS1 was confirmed by Western blot experiments with
an antibody that recognizes the N-terminal fragment of PS1.
D385A mutation inhibits PS1 endoproteolysis resulting in an
accumulation of the ,50 kDa holoprotein [27]. As expected,
expression of full-length PS1 concomitantly to a reduction in
PS1-NTF was observed in PS1 D385A-infected neurons indicat-
ing an effective competition of the PS1 D385A mutant (Fig. 2A).
As a control for the inhibitory effect on PS, we observed an
accumulation of N-cadherin-CTF in cultures infected with LV-
PS1 D385A (Fig. 2A).
In the above experiments, the proteolysis of specific neurexin
isoforms could not be assessed since both a- and b-neurexins share
common cytoplasmic tails, which are recognized by the cyto-
neurexin antibody [11]. In an attempt to investigate whether b-
neurexin proteins are processed by a PS/c-secretase activity in
neurons, we infected hippocampal neurons with recombinant LV
expressing HA-bNrx1. As compared to non-infected cells or cells
infected with GFP, overexpression of HA-bNrx1 increased the
levels of neurexin-CTFs in both non-treated and DAPT-treated
cultures (Fig. 2B). To confirm that the increase in neurexin-CTFs
levels results from the processing of HA-bNrx1, rather than from
the proteolysis of other neurexin isoforms, we expressed HA-
bNrx1 DC, a mutant b-neurexin-1 protein that lacks the
cytoplasmic tail and cannot be recognized by the cyto-neurexin
antibody (Fig. 2B). Lentiviral overexpression of HA-bNrx1 DC did
not result in an increase of neurexin-CTFs levels, as compared to
HA-bNrx1 (Fig. 2B). Overexpression of HA-bNrx1 and HA-
bNrx1 DC was confirmed by Western blot with the HA antibody
(Fig. 2B). Altogether, these results indicate that b-neurexin
isoforms are processed by a PS/c-secretase–dependent cleavage,
and that inhibition of PS/c-secretase activity using pharmacolog-
ical or genetic approaches results in the accumulation of neurexin-
CTFs in neurons.
Differential effect of FAD-linked PS1 mutations in b-
neurexin processing
Autosomal dominant mutations in PS1 and PS2 genes cause the
majority of FAD cases, although the mechanism by which these
mutations cause memory deficits are largely unclear. To analyze
the effect of FAD-linked PS1 mutations in b-neurexin processing
we used PS2/2 MEF cells, which lack PS/c-secretase activity
[30]. HA-bNrx1 was transiently expressed in WT or PS2/2
Figure 2. Accumulation of neurexin-CTFs in PS/b-secretase-deficient hippocampal neurons. A) Cultured hippocampal neurons (3–5 DIV)
were non-infected (control) or infected with recombinant lentivirus (LV) expressing: GFP, PS1 or PS1 D385A. The levels of neurexins (Nrx), PS1, N-
cadherin (N-cadh) and CASK were analyzed by Western blotting 9–10 days after infection. Non-infected cultures and cultures infected with GFP were
treated with vehicle or DAPT for the last 14 hours. FLa: full-length a-neurexins; FLb: full-length b-neurexins. B) Hippocampal neurons were non-
infected or infected with LV-GFP, LV-HA-bNrx1 or LV-HA-bNrx1 DC and treated with vehicle or DAPT, as above. The expression of HA-tagged b-
neurexin proteins and neurexin-CTFs was analyzed by Western blotting with an anti-HA and cyto-neurexin antibodies, respectively. a-Actin levels
were used as loading control.
doi:10.1371/journal.pone.0019430.g002
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variants. The ability of FAD-linked PS1 mutants to rescue the
accumulation of neurexin-CTFs in PS2/2 cells was analyzed by
Western blotting. In agreement with the above data, expression of
HA-bNrx1 led to a robust increase in neurexin-CTFs in PS2/2
MEF cells (Fig. 3). Furthermore, co-expression of PS1 in PS2/2
MEF cells efficiently reduced the accumulation of neurexin-CTFs
to basal levels, confirming that PS1/c-secretase activity is required
for normal b-neurexin processing (Fig. 3). Interestingly, the PS1
M146L and PS1 H163R mutants efficiently rescued the normal
processing of HA-bNrx1 to the levels of PS1 (Fig. 3). By contrast,
expression of PS1 C410Y and PS1 DE9 mutants failed to rescue the
normal processing of HA-bNrx1, despite they were expressed at
similar levelsthan PS1(Fig. 3).Similarly, expression of PS1WT and
the FAD-linked PS1 mutants M146L and H163R decreased the
accumulation of endogenous N-Cadherin-CTF in MEF PS2/2
cells, while the expression of PS1 C410Y and PS1 DE9 did not alter
N-Cadherin-CTFlevels(Fig.3).Itisimportanttonotethat transient
Figure 3. The processing of b-neurexin-1 is differentially affected by FAD-linked PS1 mutants. A) PS+/+ or PS2/2 MEF cells were
transfected with vector or co-transfected with HA-bNrx1 and the following plasmids: empty vector, PS1 WT or the FAD-linked mutants PS1 M146L,
PS1 H163R, PS1 C410Y or PS1 DE9. Cell lysates were subjected to Western blotting analysis with the cyto-neurexin (Nrx), N-cadherin (N-cadh), PS1 and
Nicastrin (NCT) antibodies. To study PS1 expression, two different PS1 antibodies recognizing both mouse (m) and human PS1 (PS1 loop antibody) or
mouse PS1 (Ab-2 antibody) were used. The endoproteolysis of PS1 (,45 kDa) generates 18–20 kDa CTFs. The expression of PS1 WT and FAD-
associated PS1 mutants increased the mature form of Nicastrin recognized as a slower migrating band in Western blot experiments. The FAD-linked
PS1 mutants C410Y and DE9 show deficient PS1 endoproteolysis and fail to rescue neurexin- and N-Cadherin-CTFs processing. b-Actin levels were
used as loading control. B) Quantitative analysis of HA-bNrx1 CTFs relative levels. Data represents mean 6 SD of three independent experiments.
Statistical significant differences are shown (***P,0.001).
doi:10.1371/journal.pone.0019430.g003
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some extent the maturation of nicastrin, which indicates incorpo-
ration of the PS proteins into the c-secretase complex. Notably, PS1
C410Y and PS1 DE9 FAD-linked mutants showed a significant
reduction of autoproteolytic cleavage [40], as indicated by the
presence of the unprocessed PS1 form of ,50 kDa (Fig. 3),
suggesting that the proteolytic processing of PS1 is required for the
efficient cleavage of neurexin-CTFs.Together, these results indicate
that some FAD-linked PS1 mutations cause a loss of function effect
in processing b-neurexins and suggest that the abnormal processing
of b-neurexins might contribute to the synaptic defects associated
with loss of PS function.
Accumulation of neurexin-CTFs in synaptic fractions of
PS cDKO mice
The above results point at a role of PS/c-secretase-dependent
processing of neurexins at synapses. To study the relevance of
neurexin processing in vivo we examined endogenous neurexin
processing in brains from PS12/2 embryos and adult PS cDKO
mice. PS12/2 mice die shortly after birth, while PS expression in
PS cDKO is selectively abolished in postnatal excitatory forebrain
neurons allowing the study of PS in mature synapses [5,31].
Consistent with a role of PS in the proteolysis of neurexins, we
found a significant accumulation of neurexin-CTFs in brain lysates
from PS12/2 embryos and PS cDKO adult mice compared with
control littermate animals (Fig. 4A). Associated with decreased PS1
levels, N-cadherin CTF was also increased in PS12/2 and PS
cDKO brains (Fig. 4A).
Previous results have demonstrated that PS localize at
presynaptic terminals and that substrates of PS/c-secretase
complex, such as APP-CTF, accumulate in presynaptic terminals
of PS knockout mice [6,38]. To determine the subcellular
localization of the accumulated neurexin-CTFs, we purified
cortical synaptosomal fractions from control and PS cDKO brains
and analyzed neurexin-CTFs and PS1 expression by Western blot
analysis. Biochemical analyses revealed a specific accumulation of
neurexin-CTFs coinciding with reduced PS1 levels in cortical
synaptosomes of PS cDKO mice. The residual levels of PS1 in the
cortex of PS cDKO mice are likely due to PS1 normal expression
in glia and interneurons [5,6]. Further subcellular fractionation
showed that PS1 was localized mainly in the synaptophysin-
enriched presynaptic fractions of control mice. Interestingly,
neurexin-CTFs were mostly accumulated in the presynaptic
fraction of PS cDKO mouse brains, although lower levels of
neurexin-CTFs were also detected in the postsynaptic fraction
(Fig. 4B). These results, which agree with our previous
Figure 4. Accumulation of neurexin-CTFs in synaptic fractions of PS cDKO mice. A) Brain lysates from PS1+/+, PS1+/2 and PS12/2 mouse
embryos (E 17.5) or 2 month-old control wild-type (WT) and PS cDKO mice were analyzed by Western blotting with the cyto-neurexin (Nrx), PS1 and
N-cadherin (N-cadh) antibodies, as indicated. Neurexin-CTFs and N-cadherin-CTF levels increased coinciding with decreased PS1 expression in animals
lacking PS. The results were replicated in at least two independent mice per condition, as shown. B) Accumulation of neurexin-CTFs in purified
synaptosomal and synaptic fractions from PS cDKO mice. Cortical brain lysates and pre- and post-synaptic fractions obtained from synaptosomal
preparations from control wild-type (WT) and PS cDKO mice were analyzed by Western blotting with the cyto-neurexin, PS1, synaptophysin (SYP) and
PSD95 antibodies. Neurexin-CTFs levels are markedly increased in synaptosomes and presynaptic fractions of PS cDKO mice. Synaptophysin and PSD-
95 are specifically enriched in the presynaptic and postsynaptic fractions, respectively.
doi:10.1371/journal.pone.0019430.g004
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PS1 cKO mice [38], indicate that PS regulates c-secretase-
dependent processing and accumulation of neurexin-CTFs at
synaptic compartments.
Expression of postsynaptic neuroligin-1 recruits PS1 to
synaptic terminals
Our data suggest that PS localizing at presynaptic terminals
might mediate the proteolysis of neurexins at glutamatergic
synapses. Therefore, we investigated whether PS are recruited to
glutamatergic terminals mediated by the neurexin-neuroligin
complex. With that purpose, we transfected cultured hippocampal
neuronswithHA-neuroligin-1(+B)(named HA-Nlg1 forsimplicity),
a major neuroligin-1 isoform that triggers glutamatergic differen-
tiation in hippocampal neurons [16]. Then, the recruitment of
endogenous PS1 and neurexins to HA-Nlg1-induced synapses was
analyzed by confocal microscopy. Consistent with previous results
[11], we found that HA-Nlg1 triggered the recruitment of neurexins
to the synaptic contacts (Fig. 5A). The recruited neurexins most
likely correspond to b-neurexin isoforms, since HA-Nlg1 binds to b-
but not a-neurexins [12,14,16]. When the distribution of PS1 was
analyzed with an antibody recognizing the N-terminal domain, we
found that PS1 was concentrated and partially overlapped with
neurexins at HA-Nlg1-induced synapses (Fig. 5A). Moreover, PS1
partially colocalized with synaptic proteins, such as PSD95 and
synaptobrevin, at HA-Nlg1 synapses (Fig. S1). Furthermore,
quantification analysis of the relative dendritic area occupied by
PS1 and neurexins revealed a significant increase in dendrites
expressing HA-Nlg1 compared to dendrites expressing GFP
(Fig. 5C). Moreover, PS1 intensity was also significantly increased
on dendrites expressing HA-Nlg1 (11465.3 in control GFP
dendrites vs 1306 5.1 in HA-Nlg1 dendrites, p,0.05). Similar
results were obtained with the Ab-2 antibody that recognizes the C-
terminal domain of murine PS1 (data not shown). These results
indicate that PS1 is accumulated at Nlg1-mediated synapses.
To analyze whether the recruitment of PS1 occurs at
presynaptic terminals, we performed a mixed-culture assay of
hippocampal neurons with HEK293 cells expressing HA-Nlg1.
This assay allows the study of the recruitment of axonal markers in
response to contact with non-neuronal cells expressing a specific
neuroligin isoform [13,41]. The localization of PS1 was analyzed
with the Ab-2 antibody that only recognizes murine PS1 (see also
Fig. 3). Therefore, recruitment of axonal PS1 to neuroligin-1
hemisynapses can be detected as enrichment of PS1 staining on
HEK293 cells expressing HA-Nlg1. In HEK293 cells expressing
GFP, the distribution of PS1 was similar in all areas of the field,
regardless of the presence of HEK293 cells (Fig. 5B). In contrast,
analysis of PS1 intensity (9361.4 in control GFP cells vs 11662.1
in HA-Nlg1 cells, p,0.001) and of the relative area occupied on
the transfected cells indicated that PS1 was specifically recruited to
HEK293 cells expressing HA-Nlg1 (Fig. 5B and 5D). Triple
immunofluorescence staining and quantitative analyses revealed
that axonal neurexins were also recruited to HA-Nlg1 hemi-
synapses (Fig. 5B and 5D). These data, which are consistent with
the presynaptic localization of PS1 shown by biochemical
experiments, strongly suggest that expression of HA-Nlg1 in
dendrites triggers the recruitment of axonal PS1 at the presynaptic
sites mediated by b-neurexins.
PS1 regulates the recruitment of neurexins to
neuroligin-1 synapses
After showing that PS1 is concentrated at glutamatergic
terminals mediated by HA-Nlg1, we investigated whether blocking
PS function increases neurexin-CTFs levels at these terminals. To
explore this possibility, we infected cultured hippocampal neurons
with lentiviral vectors expressing GFP, PS1 or the dominant
negative mutant PS1 D385A for 9–10 days. Then, HA-Nlg1 was
expressed in isolated neurons by transfection and accumulation of
neurexins to transfected dendrites was studied with the cyto-
neurexin antibody. We reasoned that accumulation of neurexin-
CTFs could be visualized as an increase in fluorescence staining
detected with the cyto-neurexin antibody. Indeed, we observed
increased cyto-neurexin staining at HA-Nlg1-mediated synapses in
neurons expressing PS1 D385A, as compared to GFP or PS1-
infected neurons (Fig 6A). Quantification analysis of multiple
confocal images showed an increase in the relative dendritic area
occupied by neurexin in neurons expressing PS1 D385A (Fig. 6C).
In the above experiments PS1 was overexpressed in both the
pre- and postsynaptic neurons. To determine whether the
accumulation of neurexins is due to a presynaptic effect of PS1
rather than an effect of PS1 in the postsynaptic cell, we adapted
the mixed-culture assays described before to inhibit PS1 function
selectively at axons contacting HA-Nlg1-expressing cells. For that,
hippocampal neurons at 3 DIV were infected with lentiviral
vectors expressing GFP, PS1 or PS1 D385A for 9–10 days and
then co-cultured with HEK293 cells expressing HA-Nlg1. Thus,
the expression of exogenous PS1 was restricted to axons at the
time of synaptic differentiation, while the postsynaptic HEK293 cells
expressing HA-Nlg1 were not affected. Again, we found that
axonal expression of PS1 D385A increased the presynaptic
recruitment of neurexins (Fig. 6B and 6D). Taken together, these
studies indicate that PS regulate the processing and accumulation
of neurexin-CTFs at presynaptic terminals of glutamatergic
synapses.
Discussion
Neurexins belong to a large family of plasma membrane
proteins with synaptic function. In this study, we show that PS/c-
secretase mediates the cleavage of neurexins at synapses.
Inhibition of PS/c-secretase results in the accumulation of
neurexin-CTFs in vitro and in vivo. Loss of PS function enhances
neurexin accumulation at synaptic contacts mediated by HA-Nlg1,
whereas expression of HA-Nlg1 triggers the recruitment of PS1 to
glutamatergic terminals. Moreover, neurexin-CTFs mostly accu-
mulate at presynaptic terminals of PS cDKO mice coinciding with
initial synaptic and memory impairments and prior to the onset of
neurodegeneration, suggesting that impaired neurexin processing
caused by loss of PS function is an early event in the synaptic
plasticity and memory deficits observed in PS cDKO mice.
Based on biochemical analyses, we demonstrate that neurexins
are sequentially cleaved by metalloprotease- and PS/c-secretase-
dependent activities. Expression of epitope-tagged a- and b-
neurexin isoforms in heterologous cells generates neurexin-CTFs,
which abnormally accumulate in the presence of the PS/c-
secretase inhibitor DAPT. Immunoprecipitation of conditioned
media of HEK293 cells transfected with HA-bNrx1 and treated
with the metalloprotease inhibitor GM6001 revealed that
neurexin-CTFs are generated after shedding of the extracellular
domain. Interestingly, the ectodomain of APP is shed by a- and b-
secretases at alternative sites within the extracellular region,
yielding a-CTF and b-CTF fragments that are substrates of PS/c-
secretase [35]. In this line, we show that neurexin-CTFs appear as
two distinct species of ,12–15 kDa, suggesting the possibility that,
similarly to APP, differential cleavage in the extracellular domain
of neurexin generates CTFs of distinct sizes. Although the
functional significance of neurexin ectodomain shedding by
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rule out the involvement of other proteases, our results with the
TAPI-1 inhibitor suggest a role of TACE/ADAM17 metallopro-
tease in the shedding of b-neurexins-1 and -2, as recently
demonstrated for b-neurexin-3 [36].
Ectodomain shedding of type I proteins by metalloproteases is
usually followed by regulated transmembrane cleavage by the c-
secretase complex [35]. It has been reported that inactivation of c-
secretase by genetic ablation or mutation of the aspartate residues
within the active site of PS1 diminishes APP cleavage and Ab
Figure 5. Recruitment of PS1 to neurexin/neuroligin mediated synapses. A) Confocal images of cultured hippocampal neurons transfected
with GFP or HA-Nlg1 at 10–13 DIV and stained with PS1 (PS1 N-terminal antibody, red in the colocalization) and cyto-neurexin antibodies (blue in the
colocalization) two days after transfection. PS1 is recruited along neurexins to HA-Nlg1 transfected dendrites. B) Hippocampal neurons (14–16 DIV)
were co-cultured with HEK293 cells expressing GFP or HA-Nlg1 for 24 hours. The recruitment of PS1 and neurexins to the transfected HEK293 cells
was analyzed by immunofluorescence with PS1 (Ab-2 antibody, red in the colocalization) and cyto-neurexin antibodies (blue in the colocalization).
The Ab-2 antibody does not recognize human PS1 expressed in HEK293 cells. In A) and B) HA-Nlg1 expression was analyzed with a HA antibody and
GFP expression was detected by direct fluorescence. C, D) Quantitative analysis of the recruitment of PS1 and neurexins to dendrites (C) or HEK293
cells (D) transfected with GFP or HA-Nlg1, as indicated. Recruitment was quantified as the relative area occupied by each specific marker in the
transfected cell. Data collected from three (C, n=25 cells per condition) or two (D, n=20 cells per condition) independent experiments are shown.
Asterisks indicate significant statistical differences (*P,0.05; ***P,0.001). Data are expressed as means 6 SEMs. Scale bars: 5 mm.
doi:10.1371/journal.pone.0019430.g005
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PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e19430Figure 6. Recruitment of neurexins to HA-Nlg1-mediated synapses in PS1-deficient neurons. A) Confocal images showing the
recruitment of neurexins to HA-Nlg1 synapses in hippocampal cultures overexpressing PS1 or PS1 D385. Hippocampal neurons were infected at 3 DIV
with LV-GFP, LV-PS1 or LV-PS1 D385, as indicated. The cultures were transfected 9 days after infection (12 DIV) with HA-Nlg1 and the localization of
HA-Nlg1 (middle panels, red in the colocalization), and neurexins (lower panels, blue in the colocalization) was analyzed by immunofluorescence 2–3
days after transfection. The fluorescence signal obtained with the cyto-neurexin antibody is increased in dendrites expressing PS1 D385. B)
Recruitment of neurexins to HEK293 cells expressing HA-Nlg1 in neuronal cultures overexpressing PS1 proteins. Hippocampal neurons infected with
LV-GFP, LV-PS1 or LV-PS1 D385 at 3 DIV were co-cultured at 12 DIV with HEK293 cells expressing HA-Nlg1 for 24 hours. The cultures were co-stained
with HA and neurexin antibodies, as above. The expression of exogenous PS1 proteins in these hemisynapses is restricted to axons contacting HA-
Nlg1 expressing cells. C, D) Quantification of neurexin recruitment to dendrites (C) or HEK293 cells (D) expressing HA-Nlg1. Pooled data collected from
three independent experiments are shown (n.24 cells per condition). Data are expressed as means 6 SEMs. ***P,0.001. Scale bars: 5 mm.
doi:10.1371/journal.pone.0019430.g006
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substrates, such as Notch and N-cadherin [27,39,42–44]. Consis-
tent with a role of PS/c-secretase in the regulation of neurexin
processing, we show that pharmacological or genetic inactivation
of PS function by using DAPT or by expressing the dominant
negative PS1 D385A mutant results in the accumulation of
neurexin-CTFs in hippocampal neurons. Similarly, neurexin-
CTFs levels are increased in brain lysates of both PS12/2
embryos and adult PS cDKO mice, confirming that neurexins are
processed by PS/c-secretase in vivo.
One of the key findings of our study is that neurexins are
proteolytically processed by PS/c-secretase at synapses, mostly at
presynaptic terminals. It is worth noting that although neurexins
were originally proposed as presynaptic proteins [45], immuno-
histochemical and electrophysiological studies have identified
neurexin functions at both pre- and postsynaptic sites
[11,25,46,47]. In addition, neurexins accumulate intracellularly
at the cell body of neurons [11]. Therefore, a relevant question
regarding the regulation of neurexins by PS is to determine
whether PS/c-secretase mediates the processing of neurexins at
synapses. By analyzing synaptosomal fractions from adult mice, we
were able to detect low levels of neurexin-CTFs at the presynaptic
fraction of control mice, which were robustly increased in PS
cDKO mice. In addition, neurexin-CTFs were accumulated at
lower levels in the postsynaptic fraction of PScDKO mice. The
subcellular localization of neurexin-CTFs resembles that of APP
CTFs, which accumulate mainly in presynaptic compartments in
PS1cKO mice [38]. The fact that PS are deleted specifically in
glutamatergic neurons in PS cDKO mice strongly suggests that the
PS-dependent proteolysis of neurexins takes place at glutamatergic
synapses, and lack of PS expression or function would result in
accumulation of neurexin-CTFs at glutamatergic synapses.
Accordingly, we found that loss of PS1 function by expression of
the PS1 D385A mutant increases neurexin signal at glutamatergic
terminals induced by HA-Nlg1. This effect is likely mediated by
presynaptic PS, as suggested by our experiments where the
function of PS1 was inhibited in axons contacting HA-Nlg1
expressing HEK293 cells. Importantly, we found that co-culture of
hippocampal neurons with HEK293 cells expressing HA-Nlg1
recruits PS1 to glutamatergic terminals, thus concentrating PS1
within the same synaptic compartment as b-neurexins. Since b-
neurexins and HA-Nlg1 participate in a trans-synaptic mechanism
that mediates glutamatergic differentiation [12,16–19,48], our
results suggest that PS-mediated neurexin processing could affect
glutamatergic synapse assembly and/or function.
We have recently shown that PS expression in postnatal mouse
brain is required for maintaining normal synaptic function and
memory [5]. Accordingly, conditional inactivation of both PS genes
in forebrain glutamatergic neurons results in synaptic and memory
deficits in PS cDKO mice at 2 months of age, which are followed by
progressive neurodegeneration at 4–6 months [5,49]. The early
synaptic deficits in PS cDKO mice are associated with impaired
paired-pulse facilitation and NMDA receptor-mediated responses,
and long-term potentiation (LTP) deficits [5]. These deficits are
likely caused by a PS-dependent presynaptic mechanism. Thus, PS
expressed presynaptically, but not postsynaptically, are required for
neurotransmitterreleaseandinductionofLTPinSchaffer-collateral
pathway synapses [6]. These observations indicate that PS acting by
a presynaptic mechanism regulate glutamatergic neurotransmitter
release and LTP induction and suggest that impaired proteolysis of
PS substrates may contribute to the synaptic defects caused by loss
ofPSfunction.Itisnoteworthythatthe cytoplasmictailofneurexins
associates with a molecular complex formed by CASK and
components of the neurotransmitter release machinery [50], and
that presynaptic b-neurexins are required for maintaining the
release probability at neuroligin-1 synapses in CA3 hippocampal
neurons [51]. Our data showing that neurexin processing is mostly
impaired in presynaptic terminals of PS cDKO mice suggest that
neurexins are potential candidates to mediate the synaptic defects
associated with loss of PS function. Additionally, the processing of
neurexinsmight regulate the function ofthe postsynapsesbya trans-
synaptic mechanism mediated by neuroligins. The accumulation of
neurexin-CTF at synaptosomes of PScDKO mice suggests the
possibility that the proteolytic shedding of neurexin ectodomain can
take place at glutamatergic synapses and, thereby, it may affect the
binding with neuroligins located at the postsynaptic terminal.
More than 180 autosomal dominant inherited mutations in the
PS genes are responsible for the majority of early-onset familial
FAD cases (http://www.molgen.ua.ac.be/ADMutations). Muta-
tions in PS alter the c-secretase-dependent cleavage of APP,
resulting in altered levels of amyloidogenic Ab peptides. PS
pathogenic mutations have distinct effects on the c - and/or e-
secretase-dependent cleavages of different substrates including
Notch, APP and N-Cadherin [39,44,52]. These data have lead to
the hypothesis that FAD-linked PS mutations may act through a
partial loss of function mechanism [7]. Notably, here we show that
some FAD-linked PS1 mutations are not able to rescue the normal
processing of b-neurexin-1 when expressed in a PS null
background. Specifically, FAD-linked mutations with the lowest
levels of endoproteolysis, C410Y and DE9, fail to rescue the
normal processing of b-neurexin-1. Some FAD-linked mutations,
including C410Y and DE9, have been previously shown to
negatively affect PS1 endoproteolysis or they alter the precise
presenilinase cleavage of PS1 [53], although the mutant PS1
proteins are incorporated into the c-secretase complex
[40,44,54,55]. In agreement with this result, we found that the
maturation of nicastrin is increased in PS2/2 cells expressing
H163R, C410Y and DE9 mutants, although at lower levels than
PS1 WT and M146L proteins. We therefore suggest that there is a
differential effect of FAD-linked PS1 mutations on c-secretase-
dependent neurexin processing, as it is the case for other
substrates. The relationship between PS endoproteolysis and PS/
c-secretase activity is still controversial. For instance, there is
evidence that cleavage of PS and formation of heterodimeric PS
NTFs and CTFs complexes is required for complete stabilization
and function of PS/c-secretase [24,27,56]. By contrast, other
reports indicate that the amyloidogenic function of c-secretase
seems to be independent of PS endoproteolysis [57]. While this
manuscript was in preparation, Bot et al. reported the shedding of
b-neurexin-3 by a- and c-secretase activities in heterologous cells
[36]. Our results showing the processing of different a- and b-
neurexin isoforms are consistent with a more general mechanism
of neurexin shedding by PS, and importantly, demonstrate that
such processing occurs at synapses during synaptic assembly.
Finally, it is worth mentioning that the previous identification of
mutations in the NRXN1 gene affecting a and b isoforms
associated with autism, mental retardation and schizophrenia
strongly suggests a role for synaptic defects mediated by neurexins
in mental diseases [23]. The data reported here showing the
processing of b-neurexin-1 and the effect of FAD-linked PS1
mutations could point at a dysfunction of neurexins in a broader
range of brain disorders.
Supporting Information
Figure S1 Colocalization of PS1 with synaptic markers
at HA-Nlg1-induced synapses. Confocal images of cultured
hippocampal neurons transfected with HA-Nlg1 and co-stained
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antibody (red in the colocalization) and the presynaptic marker
synaptobrevin (VAMP2 antibody, blue in the colocalization)
(upper panels) or the postsynaptic marker PSD95 (blue in the
colocalization) (lower panels). Arrows indicate colocalization of
PS1 with synaptic markers at HA-Nlg1-mediated synapses. Scale
bar: 5 mm.
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